Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Lymphocytic Leukemia Prognosis
New chronic lymphocytic leukemia prognosis research from General Hospital outlined
May 21st, 2008
A new study, 'Controversies in the front-line management of chronic lymphocytic leukemia,' is now available. "Once considered a simple homogeneous disease, chronic lymphocytic leukemia (CLL) is now recognized to be a heterogeneous lymphoid malignancy with patients classified into low, intermediate, and high-risk categories based on traditional and novel prognostic factors. Purine nucleoside analogues have been the standard first-line approach for over a decade," investigators in the United States report. "The recognition of synergistic activity between purine analogues, alkylating agents, and monoclonal antibodies has allowed the introduction of many new active...
Source: Immunotherapy Weekly (2008-05-21)
|
